Evidence map›Paper›PMID 37264256›Full record

ArticleJournal of neuro-oncology2023

Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.

Mario Caccese, Isacco Desideri, Marta Padovan, Francesco Bruno, Giulia Cerretti, Alba Fiorentino, Luca Denaro, Franco Chioffi, Alessandro Della Puppa, Marta Maccari and 6 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Mario CacceseDepartment of Oncology, Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy. mario.caccese@iov.veneto.it.
Isacco DesideriDepartment of Experimental and Clinical Biomedical Sciences, Radiation Oncology, Careggi Hospital, University of Florence, Florence, Italy.
Marta PadovanDepartment of Oncology, Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Francesco BrunoDivision of Neuro-Oncology, Department Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
Giulia CerrettiDepartment of Oncology, Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Alba FiorentinoDepartment of Medicine, LUM Giuseppe Degennaro University, Casamassima, Bari, Italy.
Luca DenaroAcademic Neurosurgery, Department of Neurosciences DNS, University of Padua, Padua, Italy.
Franco ChioffiDepartment of Neurosurgery, Padua University Hospital, Padua, Italy.
Alessandro Della PuppaNeurosurgical Clinical Department of Neuroscience, Psychology, Pharmacology and Child Health, Careggi Hospital, University of Florence, Florence, Italy.
Marta MaccariDepartment of Oncology, Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Francesco CavallinIndependent Statistician, Solagna, Italy.
Marina CoppolaPharmacy, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Alice PittaroRadiology Unit, Department of Imaging and Medical Physics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Roberta RudàDivision of Neuro-Oncology, Department Neuroscience, University and City of Health and Science Hospital, Turin, Italy.
Lorenzo LiviDepartment of Experimental and Clinical Biomedical Sciences, Radiation Oncology, Careggi Hospital, University of Florence, Florence, Italy.
Giuseppe LombardiDepartment of Oncology, Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy.
Istituto Oncologico Veneto · ITUniversity of Florence · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Padua · ITIstituto Nazionale di Statistica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRegorafenib demonstrated encouraging results in recurrent glioblastoma patients. Some studies showed that changes in circulating thyroid hormones (fT3, fT4, fT3/fT4 ratio) can be considered as prognostic factors in patients with various types of tumors. We designed this study to investigate the relationship between baseline thyroid variables and outcome in IDH-wild type GBM patients who were treated with regorafenib.

methodsThis multicenter retrospective study included recurrent IDH-wild-type glioblastoma patients treated with regorafenib. Only patients with baseline thyroid function values (TSH, fT3, fT4, fT3/fT4 ratio) available were evaluated. RANO criteria were used to analyze neuroradiological response. Survival curves were estimated using the Kaplan-Meier method. The relationships between baseline thyroid variables (TSH, fT3, fT4, fT3/fT4) and survival (PFS, OS) were investigated with Cox regression models.

resultsFrom November 2015 to April 2022, 134 recurrent IDH-wildtype GBM patients were treated with regorafenib and 128 of these had information on baseline thyroid function value. Median follow-up was 8 months (IQR 4.7-14.0). Objective Response Rate was 9% and Disease Control Rate was 40.9%. Median PFS was 2.7 months (95%CI 2.2-3.6) and median OS was 10.0 months (95%CI 7.0-13.0). Lower baseline TSH value in the blood was correlated with a higher rate of disease progression to regorafenib (p = 0.04). Multivariable analyses suggested a non-linear relationship between PFS (p = 0.01) and OS (p = 0.03) with baseline fT3/fT4 ratio.

conclusionIn recurrent wild-type IDH glioblastoma patients, baseline fT3/fT4 ratio showed a non-linear relationship with survival, with different impacts across the spectrum of fT3/fT4 ratio. Moreover, baseline TSH may be a predictor of regorafenib activity.

Indexed as

GlioblastomaThyroid GlandHumansNeoplasm Recurrence, LocalPhenylurea CompoundsPyridinesRetrospective StudiesThyroid Function TestsThyrotropinTriiodothyroninePhenylurea CompoundsPyridinesregorafenibThyrotropinTriiodothyroninefT3/fT4GlioblastomaRegorafenibThyroid

Identifiers

PMID37264256
PMCPMC10322943
OpenAlexW4378976178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.